![PRD_000219 PRD_000219](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000219.svg) | PRD_000219 | Name: | GRAMICIDIN S | Formula: | C60 H92 N12 O10 | Description: | GRAMICIDIN S IS A DECAPEPTIDE,
RESIDUES 1 AND 10 FORM A PEPTIDE BOND
RESULTING IN CYCLIZATION. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000220 PRD_000220](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000220.svg) | PRD_000220 | Name: | FEGLYMYCIN | Formula: | C95 H97 N13 O30 | Description: | FEGLYMYCIN IS A LINEAR HELICAL TRIDECAMER PEPTIDE | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000221 PRD_000221](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000221.svg) | PRD_000221 | Name: | Nosiheptide | Formula: | C51 H46 N13 O11 S6 | Description: | NOSIHEPTIDE IS A HETROCYCLIC THIOPEPTIDE, CONSISTING OF FIVE THIAZOLES AND ONE 3-HYDROXYPYRIDINE RINGS. A MODIFIED
INDOLE RING NO1(14) IS LINKED VIA THE SIDE CHAINS OF 3-HYDROXY 3GL(6) AND CYS(8). THE OBSERVED C-TERMINAL AMINO GROUP
NH2(13) IS LIKELY TO BE A POST-TRANSLATIONAL DECARBOXYLATED REMNANT OF A SER C-TERMINAL RESIDUE | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000222 PRD_000222](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000222.svg) | PRD_000222 | Name: | RAMOPLANIN A2 | Formula: | C119 H154 Cl N21 O40 | Description: | RAMOPLANIN A2 IS A CYCLIC HEPTADECAMER
LIPOGLYCODEPSIPEPTIDE.
THE SCAFFOLD IS A HEPTA CYCLIC PEPTIDE
GLYCOSYLATED BY ONE DISACCHARIDE AND A FATTY ACID
AT THE N-TERM. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000223 PRD_000223](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000223.svg) | PRD_000223 | Name: | THIOSTREPTON | Formula: | C72 H84 N19 O18 S5 | Description: | Thiostrepton is a hetrocyclic thiopeptide belonging to the
thiocillin family, consisting of four thiazole, one thiozoline and one
piperideine rings. A modified quinoline linked to main-chain residue 1
and side-chain of residue 12. Post translational maturation of
thiazole and oxazole containing antibiotics involves the enzymic
condensation of a Cys or Ser with the alpha-carbonyl of the preceding
amino acid to form a thioether or ether bond, then dehydration to form
a double bond with the alpha-amino nitrogen. Thiazoline or oxazoline
ring are dehydrogenated to form thiazole or oxazole rings. the
pyridinyl involves the cross-linking of a Ser and a Cys-Ser pair
usually separated by 7 or 8 residues along the peptide chain. The Ser
residues are dehydrated to didehydroalanines, then bonded between
their beta carbons. The alpha carbonyl of the Cys condenses with alpha
carbon of the first Ser to form a pyridinyl ring. The ring may be
mutiply dehydrogenated to form a pyridine ring with loss of the amino
nitrogen of the first Ser. The amidation of Ser-17 probably does not
occur by the same mechanism, oxidative cleavage of glycine, as in
eukaryotes. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000225 PRD_000225](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000225.svg) | PRD_000225 | Name: | GE2270a | Formula: | C56 H58 N15 O10 S6 | Description: | GEA2270A IS A THIOPEPTIDE CONSISTING OF ONE
PYRIDINE, ONE OXAZOLE AND FIVE THIAZOLE RINGS.
THE OBSERVED C-TERMINAL AMINO GROUP NH2(15) IS
LIKELY TO BE A POST-TRANSLATIONAL DECARBOXYLATED
REMNANT OF A SER C-TERMINAL RESIDUE. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000226 PRD_000226](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000226.svg) | PRD_000226 | Name: | Viomycin | Formula: | C25 H43 N13 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000227 PRD_000227](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000227.svg) | PRD_000227 | Name: | VIRGINIAMYCIN S1 | Formula: | C43 H49 N7 O10 | Description: | VIRGINIAMYCIN S1 IS A CYLIC HEPTAPEPTIDE. THE RING IS GENERATED BY LINKING RESIDUE 2 SIDE-CHAIN AND RESIDUE 7
MAIN-CHAIN. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000228 PRD_000228](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000228.svg) | PRD_000228 | Name: | JG-365 | Formula: | C42 H68 N8 O11 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000229 PRD_000229](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/01E.svg) | PRD_000229 | Name: | (2S)-2-(3,3-dimethylbutanoylamino)-N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[(4-iodophenyl)methylamino]-4-oxo-butan-2-yl]amino]-
1,4-dioxo-4-pyrrol-1-yl-butan-2-yl]-3,3-dimethyl-butanamide | Formula: | C31 H44 I N5 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000230 PRD_000230](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/01S.svg) | PRD_000230 | Name: | N-[(2R)-2-(hydroxycarbamoyl)-4-methylpentanoyl]-L-alanylglycinamide | Formula: | C12 H22 N4 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000231 PRD_000231](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000231.svg) | PRD_000231 | Name: | N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-N-[(1S)-1-(carboxymethyl)-2-oxo-5-phenylpentyl]-L-valinamide | Formula: | C29 H40 N4 O11 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000232 PRD_000232](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0D3.svg) | PRD_000232 | Name: | N-[(2S)-2-benzyl-3-sulfanylpropanoyl]-L-alanylglycinamide | Formula: | C15 H21 N3 O3 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000233 PRD_000233](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000233.svg) | PRD_000233 | Name: | N-acetyl-3-cyclohexyl-L-alanyl-N~5~-[amino(iminio)methyl]-L-ornithyl-L-alanyl-L-methionyl-S-[(acetylamino)methyl]-L-
cysteinyl-L-seryl-L-leucinamide | Formula: | C40 H73 N12 O10 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000234 PRD_000234](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0D6.svg) | PRD_000234 | Name: | N-{(1R)-3-phenyl-1-[2-(phenylsulfonyl)ethyl]propyl}-N~2~-(piperazin-1-ylcarbonyl)-L-leucinamide | Formula: | C28 H40 N4 O4 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000235 PRD_000235](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000235.svg) | PRD_000235 | Name: | N-acetyl-L-leucyl-L-alanyl-N-[(1R,2R)-2-hydroxy-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl]-L-alaninamide | Formula: | C22 H39 N5 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000236 PRD_000236](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000236.svg) | PRD_000236 | Name: | N-acetyl-L-alanyl-N-{(1S)-3,3-difluoro-1-(1-methylethyl)-2,4-dioxo-4-[(2-phenylethyl)amino]butyl}-L-prolinamide | Formula: | C25 H37 F2 N4 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000237 PRD_000237](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0DB.svg) | PRD_000237 | Name: | N-({1-[(2S)-2-carboxy-4-phenylbutyl]cyclopentyl}carbonyl)-L-tryptophan | Formula: | C28 H32 N2 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000238 PRD_000238](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000238.svg) | PRD_000238 | Name: | Ac-Asp-Glu-Val-Asp-CMK | Formula: | C21 H31 Cl N4 O11 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000239 PRD_000239](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000239.svg) | PRD_000239 | Name: | N-acetyl-L-alpha-aspartyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-fluoro-2-oxopropyl]-L-alaninamide | Formula: | C19 H29 F N4 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000240 PRD_000240](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000240.svg) | PRD_000240 | Name: | N-acetyl-L-isoleucyl-L-prolyl-L-Phenylalaninal | Formula: | C22 H33 N3 O4 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000241 PRD_000241](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000241.svg) | PRD_000241 | Name: | N-acetyl-L-leucyl-L-alpha-aspartyl-L-alpha-glutamyl-L-seryl-L-aspartic aldehyde | Formula: | C24 H39 N5 O13 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000242 PRD_000242](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000242.svg) | PRD_000242 | Name: | N-acetyl-L-leucyl-L-phenylalanyl-N-[(1S,2R)-1-(2-carboxyethyl)-3-fluoro-2-hydroxypropyl]-L-phenylalaninamide | Formula: | C32 H43 F N4 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000243 PRD_000243](https://data.pdbjbk1.pdbj.org/pdbjplus/data/prd/svg/PRD_000243.svg) | PRD_000243 | Name: | N-acetyl-3-(naphthalen-1-yl)-L-alanyl-L-valyl-L-leucyl-L-alanyl-L-alpha-glutamyl-3-naphthalen-1-yl-
L-alaninamide | Formula: | C47 H59 N7 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000244 PRD_000244](https://data.pdbjbk1.pdbj.org/pdbjplus/data/cc/svg/0DO.svg) | PRD_000244 | Name: | (2R,4S)-N-tert-butyl-1-[(2S,3S)-3-{[(2,6-dimethylphenoxy)acetyl]amino}-2-hydroxy-4-phenylbutyl]-4-(pyridin-4-ylsulfonyl)piperidine-2-carboxamide | Formula: | C35 H46 N4 O6 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|